6272 related articles for article (PubMed ID: 21061759)
21. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
[TBL] [Abstract][Full Text] [Related]
22. PLZF regulates CCR6 and is critical for the acquisition and maintenance of the Th17 phenotype in human cells.
Singh SP; Zhang HH; Tsang H; Gardina PJ; Myers TG; Nagarajan V; Lee CH; Farber JM
J Immunol; 2015 May; 194(9):4350-61. PubMed ID: 25833398
[TBL] [Abstract][Full Text] [Related]
23. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.
von Euw E; Chodon T; Attar N; Jalil J; Koya RC; Comin-Anduix B; Ribas A
J Transl Med; 2009 May; 7():35. PubMed ID: 19457253
[TBL] [Abstract][Full Text] [Related]
24. The gene expression and immunohistochemical time-course of diphenylcyclopropenone-induced contact allergy in healthy humans following repeated epicutaneous challenges.
Mose KF; Burton M; Thomassen M; Andersen F; Kruse TA; Tan Q; Skov L; Røpke MA; Litman T; Clemmensen O; Kristensen BW; Friedmann PS; Andersen KE
Exp Dermatol; 2017 Oct; 26(10):926-933. PubMed ID: 28370374
[TBL] [Abstract][Full Text] [Related]
25. CD70 and Th17 are involved in human contact sensitivity.
Lee DS; Gulati N; Martiniuk F; Levis WR
J Drugs Dermatol; 2011 Oct; 10(10):1192-4. PubMed ID: 21968671
[TBL] [Abstract][Full Text] [Related]
26. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
[TBL] [Abstract][Full Text] [Related]
27. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.
Bamias G; Delladetsima I; Perdiki M; Siakavellas SI; Goukos D; Papatheodoridis GV; Daikos GL; Gogas H
Cancer Invest; 2017 Aug; 35(7):443-455. PubMed ID: 28548891
[TBL] [Abstract][Full Text] [Related]
28. Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment.
Han J; Agarwal A; Young JN; Owji S; Luu Y; Poplausky D; Yassky D; Estrada Y; Ungar J; Krueger JG; Gulati N
Sci Rep; 2022 Dec; 12(1):22364. PubMed ID: 36572780
[TBL] [Abstract][Full Text] [Related]
29. Vitiligo as an adverse reaction to topical diphencyprone.
Pan JY; Theng C; Lee J; Goh BK
Ann Acad Med Singap; 2009 Mar; 38(3):276-7. PubMed ID: 19347085
[No Abstract] [Full Text] [Related]
30. Unique protein signatures evolve during the course of a delayed-type hypersensitivity reaction in human skin.
Han J; Stratman S; Young JN; Poplausky D; Owji S; Luu Y; Estrada Y; Correa da Rosa J; Krueger JG; Gulati N
J Dermatol; 2023 Jun; 50(6):804-809. PubMed ID: 36578124
[TBL] [Abstract][Full Text] [Related]
31. Collision tumor of primary laryngeal mucosal melanoma and invasive squamous cell carcinoma with IL-17A and CD70 gene over-expression.
Sirikanjanapong S; Lanson B; Amin M; Martiniuk F; Kamino H; Wang BY
Head Neck Pathol; 2010 Dec; 4(4):295-9. PubMed ID: 20697851
[TBL] [Abstract][Full Text] [Related]
32. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
33. PLZF Controls the Development of Fetal-Derived IL-17+Vγ6+ γδ T Cells.
Lu Y; Cao X; Zhang X; Kovalovsky D
J Immunol; 2015 Nov; 195(9):4273-81. PubMed ID: 26408661
[TBL] [Abstract][Full Text] [Related]
34. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
[TBL] [Abstract][Full Text] [Related]
36. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Attia P; Phan GQ; Maker AV; Robinson MR; Quezado MM; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Restifo NP; Haworth LR; Levy C; Mavroukakis SA; Nichol G; Yellin MJ; Rosenberg SA
J Clin Oncol; 2005 Sep; 23(25):6043-53. PubMed ID: 16087944
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients.
Brunner G; Reitz M; Schwipper V; Tilkorn H; Lippold A; Biess B; Suter L; Atzpodien J
Cancer Biother Radiopharm; 2008 Aug; 23(4):451-9. PubMed ID: 18771349
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulation of malignant melanoma by contact sensitizing agents.
Trowbridge RM; Mitkov MV; Pittelkow MR; Agrawal DK
Expert Rev Clin Immunol; 2014 Jan; 10(1):63-76. PubMed ID: 24308833
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
40. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
Reuben JM; Lee BN; Li C; Gomez-Navarro J; Bozon VA; Parker CA; Hernandez IM; Gutierrez C; Lopez-Berestein G; Camacho LH
Cancer; 2006 Jun; 106(11):2437-44. PubMed ID: 16615096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
